Acute-on-Chronic Liver Failure in Budd-Chiari Syndrome: Profile and Predictors of Outcome.
Ascites
Cirrhosis
Liver
Portal hypertension
Vascular
Journal
Digestive diseases and sciences
ISSN: 1573-2568
Titre abrégé: Dig Dis Sci
Pays: United States
ID NLM: 7902782
Informations de publication
Date de publication:
09 2020
09 2020
Historique:
received:
14
10
2019
accepted:
10
12
2019
pubmed:
4
1
2020
medline:
30
12
2020
entrez:
4
1
2020
Statut:
ppublish
Résumé
There is a paucity of data on the clinical presentations and outcome of Budd-Chiari syndrome (BCS) patients presenting as acute-on-chronic liver failure (BCS-ACLF). We aimed to describe the profile and outcomes of endovascular interventions in patients with BCS-ACLF. All BCS-ACLF patients presenting between October 2007 and April 2019 satisfying the Asian Pacific Association for the Study of the Liver (APASL) definition were studied. We compared 30- , 90- and, 180-day survival among BCS-ACLF patients who underwent endovascular intervention with those who did not, and with a historical cohort of Child-C BCS patients without ACLF who underwent endovascular intervention. Twenty-eight (5%) of 553 BCS patients presented as ACLF as per APASL definition. The majority (60.7%) were males, and mean age was 29.6 ± 11.2 years. The most common site of the block was isolated involvement of hepatic veins-HV (68%), followed by combined inferior vena cava (IVC) and HV block (25%) and isolated IVC block (7%). The acute precipitants were stent thrombosis (17.9%), acute HV thrombosis (10.7%), acute viral hepatitis (7.1%), and antituberculosis drug with hepatitis B virus reactivation (3.6%). In 60.7% patients, no acute precipitant could be identified. The 30- , 90- , and 180-day survival in BCS-ACLF post-endovascular intervention (n = 15), BCS-ACLF without endovascular intervention (n = 13), and Child-C BCS without ACLF who underwent endovascular intervention (n = 25) were (93%, 87%, and 87%), (46%, 28%, and 0%) and (96%, 92%, and 88%), respectively (log-rank test, p value < 0.001). On multivariate Cox proportional analysis, endovascular intervention and the presence of hepatic encephalopathy were independent predictors of mortality. Budd-Chiari syndrome can present as acute-on-chronic liver failure. Endovascular intervention is associated with an improved outcome.
Sections du résumé
BACKGROUND AND AIM
There is a paucity of data on the clinical presentations and outcome of Budd-Chiari syndrome (BCS) patients presenting as acute-on-chronic liver failure (BCS-ACLF). We aimed to describe the profile and outcomes of endovascular interventions in patients with BCS-ACLF.
METHODS
All BCS-ACLF patients presenting between October 2007 and April 2019 satisfying the Asian Pacific Association for the Study of the Liver (APASL) definition were studied. We compared 30- , 90- and, 180-day survival among BCS-ACLF patients who underwent endovascular intervention with those who did not, and with a historical cohort of Child-C BCS patients without ACLF who underwent endovascular intervention.
RESULTS
Twenty-eight (5%) of 553 BCS patients presented as ACLF as per APASL definition. The majority (60.7%) were males, and mean age was 29.6 ± 11.2 years. The most common site of the block was isolated involvement of hepatic veins-HV (68%), followed by combined inferior vena cava (IVC) and HV block (25%) and isolated IVC block (7%). The acute precipitants were stent thrombosis (17.9%), acute HV thrombosis (10.7%), acute viral hepatitis (7.1%), and antituberculosis drug with hepatitis B virus reactivation (3.6%). In 60.7% patients, no acute precipitant could be identified. The 30- , 90- , and 180-day survival in BCS-ACLF post-endovascular intervention (n = 15), BCS-ACLF without endovascular intervention (n = 13), and Child-C BCS without ACLF who underwent endovascular intervention (n = 25) were (93%, 87%, and 87%), (46%, 28%, and 0%) and (96%, 92%, and 88%), respectively (log-rank test, p value < 0.001). On multivariate Cox proportional analysis, endovascular intervention and the presence of hepatic encephalopathy were independent predictors of mortality.
CONCLUSION
Budd-Chiari syndrome can present as acute-on-chronic liver failure. Endovascular intervention is associated with an improved outcome.
Identifiants
pubmed: 31897895
doi: 10.1007/s10620-019-06005-7
pii: 10.1007/s10620-019-06005-7
doi:
Types de publication
Comparative Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2719-2729Références
DeLeve LD, Valla D-C, Garcia-Tsao G. American Association for the study liver diseases. Vascular disorders of the liver. Hepatology. 2009;49:1729–1764.
doi: 10.1002/hep.22772
Garcia-Pagán JC, Heydtmann M, Raffa S, et al. TIPS for Budd–Chiari syndrome: long-term results and prognostics factors in 124 patients. Gastroenterology. 2008;135:808–815.
doi: 10.1053/j.gastro.2008.05.051
Shalimar, Kumar A, Kedia S, et al. Hepatic venous outflow tract obstruction: treatment outcomes and development of a new prognostic score. Aliment Pharmacol Ther. 2016;43:1154–1167.
doi: 10.1111/apt.13604
Seijo S, Plessier A, Hoekstra J, et al. Good long-term outcome of Budd–Chiari syndrome with a step-wise management. Hepatology. 2013;57:1962–1968.
doi: 10.1002/hep.26306
Parekh J, Matei VM, Canas-Coto A, Friedman D, Lee WM. Budd–Chiari syndrome causing acute liver failure: a multicenter case series. Liver Transpl. 2017;23:135–142.
doi: 10.1002/lt.24643
Fernández J, Acevedo J, Wiest R, et al. Bacterial and fungal infections in acute-on-chronic liver failure: prevalence, characteristics and impact on prognosis. Gut. 2018;67:1870–1880.
doi: 10.1136/gutjnl-2017-314240
Mücke MM, Rumyantseva T, Mücke VT, et al. Bacterial infection-triggered acute-on-chronic liver failure is associated with increased mortality. Liver Int. 2018;38:645–653.
doi: 10.1111/liv.13568
Shalimar, Rout G, Jadaun SS, et al. Prevalence, predictors and impact of bacterial infection in acute on chronic liver failure patients. Dig Liver Dis. 2018;50:1225–1231.
doi: 10.1016/j.dld.2018.05.013
Sarin SK, Kedarisetty CK, Abbas Z, Amarapurkar D, Bihari C, et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL) 2014. Hepatol Int. 2014;8:453–471.
doi: 10.1007/s12072-014-9580-2
Janssen HLA, Garcia-Pagan J-C, Elias E, et al. Budd–Chiari syndrome: a review by an expert panel. J Hepatol. 2003;38:364–371.
doi: 10.1016/S0168-8278(02)00434-8
Moreau R, Jalan R, Gines P, et al. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology. 2013;144:1437.e1–1437.e9.
doi: 10.1053/j.gastro.2013.02.042
Jalan R, Saliba F, Pavesi M, et al. Development and validation of a prognostic score to predict mortality in patients with acute-on-chronic liver failure. J Hepatol. 2014;61:1038–1047.
doi: 10.1016/j.jhep.2014.06.012
Vilstrup H, Amodio P, Bajaj J, et al. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology. 2014;60:715–735.
doi: 10.1002/hep.27210
Brancatelli G, Vilgrain V, Federle MP, et al. Budd–Chiari syndrome: spectrum of imaging findings. Am J Roentgenol. 2007;188:W168–W176.
doi: 10.2214/AJR.05.0168
Owen JM, Gaba RC. Transjugular intrahepatic portosystemic shunt dysfunction: concordance of clinical findings, doppler ultrasound examination, and shunt venography. J Clin Imaging Sci. 2016;6:29.
doi: 10.4103/2156-7514.186510
Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973;60:646–649.
doi: 10.1002/bjs.1800600817
Jones AE, Trzeciak S, Kline JA. The Sequential Organ Failure Assessment score for predicting outcome in patients with severe sepsis and evidence of hypoperfusion at the time of emergency department presentation. Crit Care Med. 2009;37:1649–1654.
doi: 10.1097/CCM.0b013e31819def97
Kamath PS, Kim WR. The model for end-stage liver disease (MELD). Hepatology. 2007;45:797–805.
doi: 10.1002/hep.21563
Montano-Loza AJ, Tandon P, Kneteman N, Bailey R, Bain VG. Rotterdam score predicts early mortality in Budd–Chiari syndrome, and surgical shunting prolongs transplant-free survival. Aliment Pharmacol Ther. 2009;30:1060–1069.
doi: 10.1111/j.1365-2036.2009.04134.x
Jalan R, Fernandez J, Wiest R, et al. Bacterial infections in cirrhosis: a position statement based on the EASL Special Conference 2013. J Hepatol. 2014;60:1310–1324.
doi: 10.1016/j.jhep.2014.01.024
Valla D-C. Primary Budd–Chiari syndrome. J Hepatol. 2009;50:195–203.
doi: 10.1016/j.jhep.2008.10.007
Hadengue A, Poliquin M, Vilgrain V, et al. The changing scene of hepatic vein thrombosis: recognition of asymptomatic cases. Gastroenterology. 1994;106:1042–1047.
doi: 10.1016/0016-5085(94)90765-X
Menon KVN, Shah V, Kamath PS. The Budd–Chiari syndrome. N Engl J Med. 2004;350:578–585.
doi: 10.1056/NEJMra020282
Shalimar, Kumar D, Vadiraja PK, et al. Acute on chronic liver failure because of acute hepatic insults: etiologies, course, extrahepatic organ failure and predictors of mortality. J Gastroenterol Hepatol. 2016;31:856–864.
doi: 10.1111/jgh.13213
Shalimar, Saraswat V, Singh SP, et al. Acute-on-chronic liver failure in India: the Indian National Association for study of the liver consortium experience. J Gastroenterol Hepatol. 2016;31:1742–1749.
doi: 10.1111/jgh.13340
O’Leary JG, Reddy KR, Garcia-Tsao G, et al. NACSELD acute-on-chronic liver failure (NACSELD-ACLF) score predicts 30-day survival in hospitalized patients with cirrhosis. Hepatology. 2018;67:2367–2374.
doi: 10.1002/hep.29773
Bajaj JS, O’Leary JG, Reddy KR, et al. Survival in infection-related acute-on-chronic liver failure is defined by extrahepatic organ failures. Hepatology. 2014;60:250–256.
doi: 10.1002/hep.27077
Engelmann C, Thomsen KL, Zakeri N, et al. Validation of CLIF-C ACLF score to define a threshold for futility of intensive care support for patients with acute-on-chronic liver failure. Crit Care. 2018;22:254.
doi: 10.1186/s13054-018-2156-0
de Franchis R. Expanding consensus in portal hypertension. J Hepatol. 2015;63:743–752.
doi: 10.1016/j.jhep.2015.05.022
Qi X, Guo W, He C, et al. Transjugular intrahepatic portosystemic shunt for Budd–Chiari syndrome: techniques, indications and results on 51 Chinese patients from a single centre. Liver Int. 2014;34:1164–1175.
doi: 10.1111/liv.12355
Shalimar, Kedia S, Mahapatra SJ, et al. Severity and outcome of acute-on-chronic liver failure is dependent on the etiology of acute hepatic insults: analysis of 368 patients. J Clin Gastroenterol. 2017;51:734–741.
doi: 10.1097/MCG.0000000000000823
Qi X, Ren W, Wang Y, Guo X, Fan D. Survival and prognostic indicators of Budd–Chiari syndrome: a systematic review of 79 studies. Expert Rev Gastroenterol Hepatol. 2015;9:865–875.
doi: 10.1586/17474124.2015.1024224